Last reviewed · How we verify
NCT05046275
MCR Syndrome in Quebec : Results From NuAge Study
trial testing Data analysis in Motoric Cognitive Risk Syndrome in 1,741 participants. Status unknown.
2 November 2025
Quick facts
| Lead sponsor | Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,741 |
| Start date | 3 November 2020 |
| Primary completion | 2 November 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Data analysis — full drug profile →
Conditions studied
- Motoric Cognitive Risk Syndrome — all drugs for Motoric Cognitive Risk Syndrome →
- Aging Disorder — all drugs for Aging Disorder →
Sponsor
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Who can join
65 and older, any sex, with Motoric Cognitive Risk Syndrome or Aging Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (MCR) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the Quebec elderly population. Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with physiological and pathological aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. Both declines in cognition and locomotion are associated, furthermore the temporal nature of their association has been unclear for a long time. Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that MCR syndrome is a pre-dementia syndrome, suggesting that low gait performance is the first symptom of dementia. The uniqueness of MCR syndrome is that it does not rely on a complex evaluation or laboratory investigations. Indeed, this syndrome combined subjective cognitive complaint and objective slow gait speed, and is easy to apply in population-based settings. Prevalence and incidence of MCR syndrome, as well as its association with incidence of cognitive decline and impairment, have never been reported in Canada. Nutrition as a determinant of successful aging: The Quebec longitudinal Study (the NuAge study) is a Quebec population-based observational cohort study performed in healthy older community-dwellers adults which provides a unique opportunity to: 1) obtain reliable estimates of MCR syndrome prevalence and incidence, 2) determine the distribution of clinical and biological (blood biomarkers and genetic) characteristics associated with MCR syndrome, 3) examine the association of MCR syndrome and its biological characteristics with cognitive decline and incidence of cognitive impairment in the Quebec elderly population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05046275
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Data analysis
Trials testing the same drug.
- NCT05612230 — A Lifecourse Map of Diseases in China · unknown
- NCT05036148 — Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of · completed
- NCT05056740 — Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic · unknown
- NCT04323709 — Levosimendan for Veno-arterial ECMO Weaning · completed
- NCT03542864 — Medical Supervised Duodenal-Enteral Feeding Treatment · NA · completed
Other recruiting trials for Motoric Cognitive Risk Syndrome
Currently open trials in the same condition.
- NCT07045259 — Effect of Exergaming Program Versus Neuromuscular Exercise in Elderly People With Motor Cognitive Risk Syndrome · NA · recruiting
- NCT06451874 — Personalized Exercise Treatments for Older Veterans With Motoric Cognitive Risk Syndrome · NA · recruiting
- NCT04275817 — Cognitive Prefrail and Frailty, and Motoric Cognitive Risk Syndrome: Prevalence and Association With Incident Adverse He · active not recruiting
Other Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal trials
Trials by the same sponsor.
- NCT06605092 — Characterization of Emotional Response Profiles Triggered by a Digital Artwork of Musicalized Impressionist Paintings · NA · recruiting
- NCT06724757 — Survey for Caregivers Aged 50 and Over · enrolling by invitation
- NCT06296199 — Music, Virtual Reality for Patients in IUGM · NA · completed
- NCT05571553 — E-health and People Living With Major Neurocognitive Disorder - CARE© and ESOGER© Applications · NA · completed
- NCT05537688 — Identification of Graphic Markers of Neurocognitive Disorders (MG) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05046275 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
- Last refreshed: 23 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05046275.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing